// App-Quantinova.ai

: BOSUTINIB FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA AFTER IMATINIB FAILURE: ≥8-YEAR UPDATE OF A PHASE 1/2 STUDY

Researchers

Presenter

  • Jorge E. Cortes

Principal Investigators

  • Tim H Brmmendorf

  • Yeow Tee Goh

  • Musa Yilmaz

  • Rebecca Bruner Klisovic

  • Simon Purcell

  • Andrea Viqueira

  • Eric Leip

  • Carlo Gambacorti-Passerini

Medical Centers

  • Georgia Cancer Center at Augusta University,Agusta ,United States

  • Uniklinik RWTH Aachen, Aachen, Germany

  • Singapore General Hospital, Singapore, Singapore

  • Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA

  • Pfizer Inc., Walton Oaks, United Kingdom

  • Pfizer Spain, Madrid, Spain

  • Pfizer Inc,Cambridge,United States

  • University of Milano-Bicocca, Monza, Italy

Locations

  • United States

  • Germany

  • Singapore

  • United Kingdom

  • Spain

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved